Edition:
United States

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

68.55USD
28 Apr 2017
Change (% chg)

$-0.03 (-0.04%)
Prev Close
$68.58
Open
$68.83
Day's High
$68.96
Day's Low
$68.25
Volume
1,962,523
Avg. Vol
2,804,773
52-wk High
$100.75
52-wk Low
$65.38

GILD.OQ

Chart for GILD.OQ

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $89,611.07
Shares Outstanding(Mil.): 1,307.24
Dividend: 0.52
Yield (%): 3.03

Financials

  GILD.OQ Industry Sector
P/E (TTM): 6.90 58.40 30.08
EPS (TTM): 9.94 -- --
ROI: 30.47 -0.42 13.25
ROE: 72.16 5.87 14.41

BRIEF-Galapagos announces new phase 2 proof-of-concept study with filgotinib

* Galapagos announces new phase 2 proof-of-concept study with filgotinib in cutaneous lupus erythematosus

Apr 25 2017

NASH: The next untapped pharma market gives investors many options

Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020. | Video

Apr 24 2017

UPDATE 1-NASH: The next untapped pharma market gives investors many options

April 24 Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.

Apr 24 2017

RPT-INSIGHT-NASH: The next untapped pharma market gives investors many options

April 24 Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.

Apr 24 2017

INSIGHT-NASH: The next untapped pharma market gives investors many options

April 24 Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.

Apr 24 2017

BRIEF-Gilead announces results from 2 Phase 2 studies evaluating Harvoni tablets in chronic hepatitis C infected patient populations

* Results from 2 Phase 2 studies evaluating Harvoni tablets in chronic hepatitis C infected patient populations

Apr 21 2017

BRIEF-FDA approves two of Gilead's hepatitis C drugs for pediatric patients

* U.S. FDA approves new indications for Harvoni and Sovaldi in pediatric patients 12 years and older with chronic hepatitis C infection

Apr 07 2017

BRIEF-Galapagos doses first psoriatic arthritis patient with filgotinib

* Galapagos NV - Galapagos doses first psoriatic arthritis patient with filgotinib

Apr 05 2017

BRIEF-Gilead Sciences CEO John Milligan's 2016 total compensation was $13.9 mln- SEC Filing

* Gilead Sciences Inc- CEO John F. Milligan's 2016 total compensation was $13.9 million- SEC Filing

Mar 27 2017

Gilead hepatitis C drug patent faces European challenge

LONDON International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment.

Mar 27 2017

More From Around the Web

Competitors

Earnings vs. Estimates